Pappas Ventures is making a significant investment in a Philadelphia startup that is focused on spine implant and augmentation technology.

Gentics landed $10 million in its first institutional financing. Pappas co-led the round along with Easton Capital. Ivy Capital Partners and Matigon Technologies, which is based in France, also invested.

The company, which reported making implants for the first time in May, will use the funds for pre-clinical testing and a pilot clinical study. Gentics plans to see Food and Drug Administration approval for further trials in 2008.

Its lead product, called DiscCell, is a proprietary, injectable, in-situ device designed to augment the spine.

"Gentis’ progress over the past year and their successful first in human implants in May demonstrated to the investor group the dedication of the Gentis team, the quality of their relationships in the spine market and the potential superiority of the DiscCell material over other technologies being investigated in the exciting and expanding market of spinal nucleus augmentation," said Arthur Klausner, a partner at Pappas.

Klausner, Robert Pangia of Ivy Capital, and Frank Garcia, a partner at Easton Capital, will join the Gentis board as part of the deal.

Gentis conducted a pilot clinical study in May in Brazil.